Actively Recruiting
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Led by Elisabethinen Hospital · Updated on 2024-04-30
100
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
Sponsors
E
Elisabethinen Hospital
Lead Sponsor
M
Medical University Innsbruck
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.
CONDITIONS
Official Title
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Informed consent
- Age greater than 18 years
- Diagnosed with localized pancreatic cancer recommended for upfront surgery
You will not qualify if you...
- Having a synchronous secondary malignancy
- Being pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ordensklinikum Linz Barmherzige Schwestern
Linz, Upper Austria, Austria, 4010
Actively Recruiting
Research Team
P
Patrick Kirchweger, MD, PhD
CONTACT
H
Helwig Wundsam, PD, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here